Moderna, Inc. (NASDAQ:MRNA – Get Free Report) saw unusually large options trading activity on Thursday. Stock investors purchased 143,752 call options on the company. This represents an increase of ...

Moderna, Inc, a biotechnology company ... and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus ...

Learn more about whether Insmed Incorporated or Moderna, Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.

Moderna (MRNA) stock is climbing 8% after the drug maker won a key court case and its CEO bought shares on the open market. MRNA's Court Victory A German court ruled that BioNTech (BNTX) and ...

Ghana has recorded one case of Human Metapneumovirus (hMPV). This is the first case detected since the country begun testing for human metapneumovirus hMPV in January 2025. Kwabena Mintah Akandoh ...

In a couple of regulatory filings with the SEC, it was revealed that Moderna’s CEO Stephane Bancel and director Paul Sagan acquired common stock worth $6 million. On Monday, Bancel acquired ...

The Minister for Health, Kwabena Mintah Akandoh, has confirmed the detection of a single case of Human Metapneumovirus (hMPV) in the country. He made this known while briefing Parliament on the ...

hVIVO plc (AIM: HVO), a fast-growing early-stage Contract Research Organisation (CRO) and the world leader in human challenge clinical trials, announces that, following the success of its pilot human ...